Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com
Multimodality Approaches Improve Outcomes in Marginally-Inoperable Soft Tissue Sarcoma
July 26th 2021A multimodality approach to treatment, which included sequential chemotherapy and radiation therapy followed by surgery, resulted in successful resection for most patients with marginally inoperable soft tissue sarcomas.
Read More
Venetoclax Plus Lenalidomide/Rituximab Elicits High Response Rates in Newly Diagnosed MCL
July 22nd 2021The addition of venetoclax to lenalidomide and rituximab resulted in a high response rate and encouraging minimal residual disease undetectability in patients with newly diagnosed mantle cell lymphoma—even in those with high-risk features.
Read More
A new prognostic tool, the nomogram, has demonstrated the ability to predict outcomes following treatment with lutetium-177 prostate-specific membrane antigen in patients with metastatic castration-resistant prostate cancer, and could potentially be used to inform future trial designs and clinical decisions.
Read More
Completion of Treatment Within 38 Weeks of Breast Cancer Diagnosis Linked With Improved OS
July 22nd 2021Completion of treatment options such as surgery, chemotherapy, and radiation within 38 weeks from a diagnosis with breast cancer was associated with improved survival in this population.
Read More
Ficlatuzumab Plus Chemotherapy Produces Promising Preliminary Clinical Activity in High-Risk AML
July 21st 2021The investigational therapy ficlatuzumab in combination with cytarabine demonstrated encouraging clinical efficacy with favorable tolerability when used as a treatment in patients with high-risk acute myeloid leukemia.
Read More
Nivolumab Plus Chemo or Ipilimumab Represent Potential First-Line Standards in Advanced ESCC
July 21st 2021Nivolumab plus chemotherapy or ipilimumab showcased superior overall survival over chemotherapy alone in previously untreated patients with advanced esophageal squamous cell carcinoma.
Read More
Pamrevlumab Plus Chemo Under Exploration in Novel Pancreatic Cancer Trial Platform
July 20th 2021A new experimental treatment arm examining pamrevlumab in combination with gemcitabine and nab-paclitaxel as a first- or second-line treatment for patients with metastatic pancreatic cancer has been added to the novel clinical trial platform Precision Promise, which is being conducted by the Pancreatic Cancer Action Network.
Read More
Tolaney Spotlights Tailoring Therapy by Risk in HER2+ Breast Cancer
July 16th 2021By adapting adjuvant therapy based on responses to preoperative therapy, investigators may be able to change long term outcomes for patients with HER2-positive breast cancer, creating a paradigm shift in the space.
Read More
Pevonedistat/Azacitidine Could Become New Frontline Standard for Higher-Risk MDS
July 15th 2021David Sallman, MD, discusses the role of hypomethylating agents in the treatment of patients with higher-risk myelodysplastic syndrome, the promise of pevonedistat in this population, the hunt for biomarkers of response to treatment, and remaining areas of unmet need to address with future efforts.
Read More
Darolutamide/ADT Significantly Improves OS in Nonmetastatic CRPC, Irrespective of Crossover
July 15th 2021Neal Shore, MD, FACS, discusses the impact of crossover from placebo to darolutamide on OS benefit in patients with nmCRPC enrolled to the ARAMIS trial, and next steps for the androgen receptor inhibitor.
Read More
Frontline Ibrutinib/Venetoclax Elicits Durable Responses in CLL With Undetectable MRD
July 13th 2021Fixed-duration ibrutinib plus venetoclax produced superior progression-free survival when compared with chlorambucil plus obinutuzumab in the frontline treatment of patients with chronic lymphocytic leukemia, with durable responses observed in those who achieved undetectable minimal residual disease negativity.
Read More
Spotlighting Symptom Management Strategies, Factors to Inform Treatment Decisions in Myelofibrosis
July 13th 2021Naveen Pemmaraju, MD, discusses approaches to adequately manage symptoms experienced by patients with myelofibrosis, challenges faced with defining disease progression, and strategies for when to initiate or delay treatment.
Read More
Galinpepimut-S Plus Pembrolizumab Shows Early Activity in Advanced Ovarian Cancer
July 9th 2021The combination of galinpepimut-S and pembrolizumab has demonstrated promising clinical immunobiological activity in patients with Wilms Tumor 1–positive, relapsed or refractory, platinum-resistant advanced metastatic ovarian cancer, according to results from an ad-hoc analysis of a phase 1/2 trial.
Read More
Lopes Shines a Light on the Explosion of Targeted Therapies in Lung Cancer Treatment Arsenal
June 26th 2021Gilberto Lopes, MD, discusses the latest developments made in the treatment of patients with non–small cell lung cancer whose tumors harbor genetic alterations and the clinical implications of recent regulatory approvals.
Read More
Pacritinib May Possess the Potential to Address Unmet Needs in Myelofibrosis
June 22nd 2021For patients with myelofibrosis who have platelets counts of less than 50,000, pacritinib represents a potential therapeutic option that can fill a need that has been unmet with other approved JAK inhibitors, such as ruxolitinib and fedratinib.
Read More
Oncolytic Virus/CAR T-Cell Therapy Combo Shows Preclinical Potential in Solid Tumors
June 19th 2021City of Hope has entered into a licensing agreement with Imugene Ltd. for the patents covering a combination immunotherapy that enables CD19-directed CAR T-cell therapies to target and eradicate difficult-to-treat solid tumors.
Read More